Products
Pazopanib is commercially available in the form of film-coated tablets (Votrient). It was approved in the EU and many countries in 2010.
Structure and properties
Pazopanib (C21H23N7O2S, Mr = 437.52 g/mol) exists in drugs as pazopanib hydrochloride, a white to yellowish solid that is sparingly soluble in water at pH 1 and practically insoluble above pH 4. Pazopanib is an indazole, pyrimidine, and benzenesulfonamide derivative.
Effects
Pazopanib (ATC L01XE11) has antitumor and antiangiogenic properties. Its effects are due to inhibition of several protein kinases (VEGFR, PDGFR, c-KIT). It has a long half-life of approximately 30 hours.
Indications
- Advanced and/or metastatic renal cell carcinoma.
- Advanced soft tissue sarcoma.
Dosage
According to the professional information. The tablets are usually taken once a day fasting, that is, at least one hour before or two hours after a meal.
Contraindications
- Hypersensitivity
- Severe liver dysfunction
Full details of precautions and interactions can be found in the drug label.
Interactions
Pazopanib is a substrate of CYP3A4. Corresponding drug-drug interactions are possible and must be considered during treatment.
Adverse effects
The most common possible adverse effects include digestive disturbances such as loss of appetite, abdominal pain, diarrhea, nausea, vomiting, and taste disturbances; elevation of liver enzymes; hypertension; fatigue; and changes in hair color.
